Miglustat (hydrochloride)

Miglustat (N-Butyldeoxynojirimycin) hydrochloride is an orally active and reversible ceramide glucosyltransferase inhibitor. Miglustat hydrochloride can be used for the research of type I gaucher disease[1][2].

Product Specifications

CAS Number

[210110-90-0]

Product Name Alternative

N-Butyldeoxynojirimycin (hydrochloride) ; NB-DNJ (hydrochloride) ; OGT 918 (hydrochloride)

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Glucosylceramide Synthase (GCS)

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Miglustat-hydrochloride.html

Purity

98.0

Solubility

DMSO : 65 mg/mL (ultrasonic) |H2O : ≥ 34 mg/mL

Smiles

O[C@H]1[C@H](O)[C@@H](CO)N(CCCC)C[C@@H]1O.[H]Cl

Molecular Formula

C10H22ClNO4

Molecular Weight

255.74

Precautions

H315, H319, H320

References & Citations

[1]Maria Cristina Dechecchi, et al. Anti-inflammatory effect of miglustat in bronchial epithelial cells. J Cyst Fibros. 2008 Nov;7 (6) :555-65. |[2]G D'Arcangelo, et al. Miglustat Reverts the Impairment of Synaptic Plasticity in a Mouse Model of NPC Disease. Neural Plast. 2016:2016:3830424.